Contineum Q1 2024 cash $117.9M; IPO net proceeds $108M extend runway to 2027

Contineum Therapeutics, Inc.

Cash and securities $117.9M at March 31; proforma cash (incl. IPO) $225.9M.
R&D expenses $7.8M vs $3.6M YoY; increase driven by product candidate development.
Completed IPO in April 2024; net proceeds $108.0M, extending cash runway to end of 2027.
Initiated Phase 2 trial of PIPE-307 in RRMS; J&J partner plans Phase 2 in depression in 2024.
Nominated third development candidate CTX-343 (LPA1R antagonist); IND submission expected in 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Contineum Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

today reported financial results for the first quarter ended March 31, 2024, and highlighted recent corporate progress.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Contineum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-017293

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.